Aktuellt
SENASTE
Redeye provides an update in relation to SenzaGen’s H2 2022 report. We believe the year has been strong; sales came in a bit lower than our estimates; however, EBIT is better. We have chosen to only make minor changes in our estimates for the following years; however, following an updated Redeye rating, we change the WACC from 14.5% to 13.5%, resulting in a new fair value range with a base case of SEK21 (18).
LÄS MER
